GoAI
Get started
China NT Pharma Group Company Limited logo

China NT Pharma Group Company Limited

1011.HK

HKSEHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Latest quote

HK$0.405

+HK$0.045 · +12.50%

Aug 24, 2:54 PM HKTData delayed

1011.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

China NT Pharma Group Company Limited, operating alongside its various subsidiaries, is dedicated to the full spectrum of pharmaceutical activities. This encompasses the research, development, manufacturing, commercialization, and distribution of medicinal products, serving both the People's Republic of China and international territories. The firm develops and markets prescription medications addressing a diverse array of medical conditions, including oncological and hematological diseases, gastrointestinal disorders, central nervous system afflictions, and respiratory illnesses, among other therapeutic fields. In addition to these specialized drugs, it also produces and distributes its proprietary "NT" branded products and generic formulations. Furthermore, the group extends its offerings to include marketing and promotional assistance for suppliers, alongside providing logistics and consulting solutions. Established in 1995, the company maintains its corporate headquarters in Suzhou, People's Republic of China.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
HK
CEO
Bozhi Zhang
Listed since
Apr 20, 2011
Employees
22

Market position

Day range

Current HK$0.405

52-week range

Current HK$0.405

Open
HK$0.40
Previous close
HK$0.36
Volume
3.38M
12.53× average
Average volume
269.94K
Average daily volume
Market cap
265.86M HKD
Beta
-2.01
Market reference 1
50-day average
HK$0.3868
+4.71% above average
200-day average
HK$0.6515
-37.83% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
764M CNY
P/E (TTM)
-10.11×
P/B (TTM)
-2.66×
P/S (TTM)
6.66×
EV / EBITDA
-62.03×
Earnings yield
-5.73%
Free cash flow yield
-5.44%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
16.46%
Operating margin
-39.00%
Net margin
-76.94%
Return on equity
9.51%
Return on assets
-7.49%
Return on invested capital
-28.83%

Financial health

Debt / equity
-3.01×
Current ratio
0.02×
Altman Z-score
-1
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends305%-515%-1335%-2154%Gross margin, FY2021: 64.16%Gross margin, FY2022: 60.50%Gross margin, FY2023: 100.00%Gross margin, FY2024: 13.86%Gross margin, FY2025: 39.78%Operating margin, FY2021: -43.86%Operating margin, FY2022: -12.82%Operating margin, FY2023: -763.07%Operating margin, FY2024: -34.84%Operating margin, FY2025: -51.18%Net margin, FY2021: -65.96%Net margin, FY2022: -32.07%Net margin, FY2023: -1949.36%Net margin, FY2024: -140.56%Net margin, FY2025: -107.79%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 64.16%. Gross margin FY2022 60.50%. Gross margin FY2023 100.00%. Gross margin FY2024 13.86%. Gross margin FY2025 39.78%. Operating margin FY2021 -43.86%. Operating margin FY2022 -12.82%. Operating margin FY2023 -763.07%. Operating margin FY2024 -34.84%. Operating margin FY2025 -51.18%. Net margin FY2021 -65.96%. Net margin FY2022 -32.07%. Net margin FY2023 -1949.36%. Net margin FY2024 -140.56%. Net margin FY2025 -107.79%.

Income trends

Revenue

24.16M CNY-36.36%

Operating income

−12.36M CNY+6.52%

Net income

−26.04M CNY+51.19%
Income trends across reported periods264.32M CNY113.83M CNY−36.67M CNY−187.16M CNYRevenue, FY2021: 226.7M CNYRevenue, FY2022: 207.09M CNYRevenue, FY2023: 7.37M CNYRevenue, FY2024: 37.96M CNYRevenue, FY2025: 24.16M CNYOperating income, FY2021: −99.43M CNYOperating income, FY2022: −26.54M CNYOperating income, FY2023: −56.21M CNYOperating income, FY2024: −13.23M CNYOperating income, FY2025: −12.36M CNYNet income, FY2021: −149.54M CNYNet income, FY2022: −66.41M CNYNet income, FY2023: −143.59M CNYNet income, FY2024: −53.36M CNYNet income, FY2025: −26.04M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 226.7M CNY. Revenue FY2022 207.09M CNY. Revenue FY2023 7.37M CNY. Revenue FY2024 37.96M CNY. Revenue FY2025 24.16M CNY. Operating income FY2021 −99.43M CNY. Operating income FY2022 −26.54M CNY. Operating income FY2023 −56.21M CNY. Operating income FY2024 −13.23M CNY. Operating income FY2025 −12.36M CNY. Net income FY2021 −149.54M CNY. Net income FY2022 −66.41M CNY. Net income FY2023 −143.59M CNY. Net income FY2024 −53.36M CNY. Net income FY2025 −26.04M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue24.16M CNY37.96M CNY7.37M CNY207.09M CNY226.7M CNY
Cost of goods sold14.55M CNY32.7M CNY—81.81M CNY81.24M CNY
Gross profit9.61M CNY5.26M CNY7.37M CNY125.29M CNY145.46M CNY
Research and development———3.76M CNY5.96M CNY
Selling, general, and administrative21.97M CNY18.49M CNY58.76M CNY22.62M CNY230.52M CNY
Operating expenses21.97M CNY18.49M CNY63.57M CNY26.42M CNY244.01M CNY
Interest income6.82K CNY11K CNY9K CNY40K CNY239K CNY
Interest expense27.12M CNY31.54M CNY28.82M CNY39.37M CNY88.73M CNY
Depreciation and amortization48K CNY4.58M CNY5.88M CNY21.07M CNY42.25M CNY
Operating income−12.36M CNY−13.23M CNY−56.21M CNY−26.54M CNY−99.43M CNY
Net income−26.04M CNY−53.36M CNY−143.59M CNY−66.41M CNY−149.54M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0.22

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.06-0.24-0.54-0.83Q2 '21Q4 '21Q3 '22Q2 '23Q3 '23Q1 '24Q3 '24Q1 '25
Q2 2021, reported Jun 30, 2021: actual -0.002, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual -0.095, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Aug 31, 2022: actual -0.017, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Apr 1, 2023: actual -0.023, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Sep 1, 2023: actual -0.003, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 29, 2024: actual -0.772, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 30, 2024: actual 0, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 31, 2025: actual -0.218, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.67B1.12B560.99M6.02MQ2 '21No estimateQ4 '21No estimateQ3 '22MissQ2 '23MissQ3 '23MissQ1 '24EstimateQ3 '24No estimateQ1 '25No estimate
Q2 2021, reported Jun 30, 2021: actual 133.55M HKD, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual 141.37M HKD, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Aug 31, 2022: actual 141.07M HKD, estimate 1.55B HKD, surprise -90.89%, Miss. Q2 2023, reported Apr 1, 2023: actual 98.62M HKD, estimate 1.55B HKD, surprise -93.63%, Miss. Q3 2023, reported Sep 1, 2023: actual 7.97M HKD, estimate 1.55B HKD, surprise -99.49%, Miss. Q1 2024, reported Mar 29, 2024: actual —, estimate 1.55B HKD, surprise —, Comparison unavailable. Q3 2024, reported Aug 30, 2024: actual 33.61M HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 31, 2025: actual 7.09M HKD, estimate —, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.035

2018 complete year+250.0% since 2016

Corporate action history

Dividend

Ex-dividend Jul 10, 2018

HK$0.035

Annual

Record Jul 11, 2018 · Payment Aug 2, 2018

Dividend

Ex-dividend Jun 8, 2017

HK$0.025

Annual

Record Jun 9, 2017 · Payment Jul 3, 2017

Dividend

Ex-dividend May 31, 2016

HK$0.01

Annual

Record Jun 1, 2016 · Payment Jun 15, 2016

1011.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.1

-4.23%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.74

-3.03%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$222.2

-2.54%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.40

-5.10%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.34

-5.26%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.35

-2.98%

Continue in GoAI

Research 1011.HK

research.disclaimer